Table 4.

Association of eGFR and ACR with abnormal white matter volume based on quantile regression

	Urine ACR		eGFR
Model and Comparison	Estimate ± SE	p-value	Estimate ±SE	p-value
Model 1
Continuous	0.25 (0.06)	<0.001	0.08 (0.03)	0.01
30 vs 5 mg/g (calculated)	0.44 (0.11)	–		–
300 vs 30 mg/g (calculated)	0.57 (0.14)	–		–
Model 2
Continuous	0.20 (0.05)	<0.001	0.04 (0.03)	0.2
30 vs 5 mg/g (calculated)	0.36 (0.09)	–		–
300 vs 30 mg/g (calculated)	0.46 (0.12)	–		–
Model 3
Continuous	0.17 (0.05)	0.001	0.03 (0.03)	0.3
30 vs 5 mg/g (calculated)	0.30 (0.09)	–		–
300 vs 30 mg/g (calculated)	0.38 (0.12)	–		–

Note: Data derived from the SPRINT-MIND MRI subcohort of 637 participants. The estimates denote median change. White matter volume is in cm³. For urine ACR, estimates are for each 1−U change in natural log transformed ACR. For eGFR, estimates are per each 10−ml/min/1.73m² decrease in eGFR. Model 1 is univariate. Model 2 adjusts for intracranial volume, age, MRI scanner type, education, and race. Model 3 adjusts for model 2 components as well as diabetes history, body mass index, cardiovascular disease, use of angiotensin-cnoverting enzyme inhibitors or angiotensin receptor blockers, sex, systolic blood pressure, diastolic blood pressure and either eGFR or natural log transformed urine ACR. The comparisons at clinically relevant urine ACR strata are calculated from the continuous model as: (estimate*[log(30)−log(5)]) and (estimate*[log(300)−log(5)]) for each model and can be interpreted as the estimate associated with an ACR of 30 mg/g or 300 mg/g as compared to a reference value of 5 mg/g.

ACR, albumin-creatinine ratio; eGFR, estimated glomerular filtration rate; MRI, magnetic resonance imaging; SE, standard error; SPRINT-MIND, Systolic Blood Pressure Intervention Trial-Memory and Cognition in Decreased Hypertension